0 0 0 -0.00171733561058921 0.000113862795331522 0.00228674447291 0.000929879495208291 -0.00204004174969171
Sign Up Today X
Thanks for submitting the form.
Stockreport

Intellia (NTLA) Shares Fall as CFO Glenn Goddard Steps Down [Yahoo! Finance]

Regeneron Pharmaceuticals, Inc. (REGN)  More Company Research Source: Yahoo! Finance
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
The company has appointed Edward Dulac as its new CFO, executive vice president and treasurer. He will assume his new role with effect from Jul 22, 2024. Dulac most recently served as the CFO of Fate Therapeutics. He previously held senior leadership positions at Celgene (now part of Bristol Myers) and also worked as a biopharmaceutical equity research analyst at Barclays Capital and Lehman Brothers. Year to date, shares of Intellia have plunged 24.8% compared with the industry's decline of 4.6%. Image Source: Zacks Investment Research Intellia is a genome editing company focused on developing CRISPR/Cas9-based therapeutics. The company is developing its lead in vivo genome-editing candidate, NTLA-2001, for the treatment of transthyretin (ATTR) amyloidosis. NTLA is collaborating with Regeneron Pharmaceuticals REGN for the development of NTLA-2001. NTLA-2001 is part of the company's co-development and co-promotion agreement with Regeneron. While NTLA is the lead party in t [Read more]
IMPACT SNAPSHOT EVENT TIME: REGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
REGN alerts
from News Quantified
REGN
NEWS
REGN
Earnings
REGN
Analyst Actions
REGN
SEC Filings
Stockreport

Intellia (NTLA) Shares Fall as CFO Glenn Goddard Steps Down [Yahoo! Finance]

Regeneron Pharmaceuticals, Inc.  (REGN) 
More Company Research Source: Yahoo! Finance
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
The company has appointed Edward Dulac as its new CFO, executive vice president and treasurer. He will assume his new role with effect from Jul 22, 2024. Dulac most recently served as the CFO of Fate Therapeutics. He previously held senior leadership positions at Celgene (now part of Bristol Myers) and also worked as a biopharmaceutical equity research analyst at Barclays Capital and Lehman Brothers. Year to date, shares of Intellia have plunged 24.8% compared with the industry's decline of 4.6%. Image Source: Zacks Investment Research Intellia is a genome editing company focused on developing CRISPR/Cas9-based therapeutics. The company is developing its lead in vivo genome-editing candidate, NTLA-2001, for the treatment of transthyretin (ATTR) amyloidosis. NTLA is collaborating with Regeneron Pharmaceuticals REGN for the development of NTLA-2001. NTLA-2001 is part of the company's co-development and co-promotion agreement with Regeneron. While NTLA is the lead party in t [Read more]
IMPACT SNAPSHOT
EVENT TIME:
REGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS